Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 6/20 | 0.43 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14201480 | 0.90 | SMN1; SMN2 (0.42) | TRPA1GRM2GRM3SMN1; SMN2 | |
| SCHEMBL14145254 | 0.84 | GRIK1 (0.47) | TRPA1TRPV1GRM2GRM3MAPT | |
| SCHEMBL4737745 | 0.84 | GRIK1 (0.47) | TRPA1TRPV1GRM2GRM3MAPT | |
| SCHEMBL14201454 | 0.79 | TRPA1 (0.48) | TRPA1TRPV1FAAHGRM2GRM3 | |
| SCHEMBL14145251 | 0.79 | TRPA1 (0.48) | TRPA1TRPV1FAAHS1PR2S1PR4 | |
| SCHEMBL8667484 | 0.76 | TRPA1 (0.54) | TRPA1TRPV1FAAHCES1S1PR2 | |
| SCHEMBL9620397 | 0.76 | TRPA1 (0.54) | TRPA1TRPV1FAAHCES1S1PR2 | |
| SCHEMBL14201498 | 0.75 | GRIK1 (0.50) | TRPA1GRM2GRM3GRIK1HDAC3 | |
| SCHEMBL9620206 | 0.75 | TRPA1 (0.56) | TRPA1TRPV1FAAHCES1S1PR2 | |
| SCHEMBL14201434 | 0.75 | GRIK1 (0.50) | TRPA1GRM2GRM3GRIK1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008031032-A2 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | TRANSITION THERAPEUTICS INC. (CA) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | PNLIP, CPT1A, CPT1B | TRPA1 4445/4885TRPV1 3737/4885FAAH 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.